Last reviewed: June 28, 2026
Last updated: June 28, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Both semaglutide and tirzepatide are FDA-approved GLP-1 medications that help regulate appetite and blood sugar, but they work through different pathways in your body. Clinical trials show tirzepatide produces numerically greater weight loss in some populations, though individual results vary significantly. Genetic factors influence how your body responds to each medication, making personalized selection critical for success.
How Semaglutide and Tirzepatide Differ at the Cellular Level
Semaglutide activates the GLP-1 receptor, which signals fullness in your brain and slows stomach emptying. Tirzepatide activates both the GLP-1 receptor and the GIP receptor, creating a dual-action effect that research suggests may enhance weight loss and metabolic control. This dual mechanism is why tirzepatide is sometimes described as a next-generation option, though 'better' depends entirely on your individual physiology.
The GIP receptor pathway affects energy use and fat metabolism differently than GLP-1 alone. Some people carry genetic variants that make them more responsive to GIP signaling, while others show stronger responses to GLP-1 pathways exclusively. This is why PlexusDx created the Precision Peptide Genetic Test—to identify which pathway your body favors before starting treatment.
Weight Loss Results: What Clinical Trials Show
In the SUMO clinical trials, tirzepatide produced average weight loss of 20-22% of baseline body weight over 72 weeks at the highest dose, compared to semaglutide's average of 15% in comparable trials. However, these were different patient populations tested in different studies, so direct comparison has limitations. Many patients on semaglutide achieve excellent results, particularly when their genetic profile favors GLP-1 responsiveness.
Response varies by individual, and approximately 20-30% of patients on either medication do not achieve clinically meaningful weight loss. This variability is driven partly by genetics, partly by adherence, and partly by factors like exercise and sleep that medication cannot control. Knowing your genetic predisposition before starting helps predict which medication is statistically more likely to work for your specific metabolism.
Side Effects and Tolerability Differences
Both medications carry similar side effect profiles: nausea, vomiting, constipation, and diarrhea are most common, especially during dose escalation. Tirzepatide may produce slightly more gastrointestinal side effects in some users because it activates more receptor pathways simultaneously. Starting with a low dose and escalating gradually minimizes these effects, regardless of which medication you choose.
Semaglutide is often chosen by patients who tolerate GLP-1 activity well but want to avoid additional pathway activation. Tirzepatide may suit people who tolerated semaglutide but didn't achieve sufficient weight loss, or those whose genetic profile predicts stronger GIP-pathway responsiveness. Long-term tolerability typically improves as your digestive system adapts over 4-8 weeks.
Choosing Between Them: Cost, Access, and Personalization
PlexusDx offers compounded semaglutide injections starting at $149/month and compounded tirzepatide injections starting at $249/month through licensed 503A compounding pharmacies. Both are available nationwide without insurance, and both are HSA/FSA eligible. Your dose may need to increase over time as your body adapts, but your monthly price remains flat—no surprise cost jumps based on dose escalation.
The Precision Peptide Genetic Test costs $99 as an add-on after your first month of treatment and analyzes 14 metabolic pathways across 49 peptides to show which medication pathway your genetics favor. This test examines variants in GLP1R, GIPR, FTO, and MC4R genes that influence how your body responds to each medication. For patients uncertain which medication to start with, this genetic insight dramatically improves selection accuracy and reduces trial-and-error cycles.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Which medication causes more weight loss: semaglutide or tirzepatide?
Tirzepatide showed numerically higher average weight loss (20-22%) versus semaglutide (15%) in separate clinical trials, but individual results vary widely based on genetics, lifestyle, and adherence. Some patients achieve excellent results on semaglutide alone, while others need the dual-action of tirzepatide. PlexusDx genetic testing identifies your likely responder profile before you start.
Can I switch from semaglutide to tirzepatide if I'm not losing weight fast enough?
Yes, switching between these medications is a standard clinical approach if one isn't producing desired results after 3-4 months of consistent use. Tirzepatide's dual mechanism may offer better results for patients who reach a plateau on semaglutide alone. PlexusDx providers can transition you safely and adjust your starting dose based on your prior response.
How much does tirzepatide cost at PlexusDx compared to semaglutide?
PlexusDx compounded tirzepatide injections start at $249/month, while semaglutide injections start at $149/month. Both medications maintain flat monthly pricing regardless of dose escalation, and both are HSA/FSA eligible with no insurance required or membership fees.
Are compounded semaglutide and tirzepatide as safe as brand-name versions?
PlexusDx medications are compounded by licensed 503A pharmacies following strict quality and sterility standards, making them safe and effective. While compounded versions are not FDA-approved as branded products, they contain the same active pharmaceutical ingredients as FDA-approved drugs and are legal nationwide.
What does the Precision Peptide Genetic Test tell me about semaglutide versus tirzepatide?
The test analyzes your GLP1R and GIPR genetic variants (among 14 pathways) to show whether your body favors GLP-1 signaling alone or benefits from dual GLP-1 and GIP activation. Variants like rs6923761 in GLP1R and rs1800437 in GIPR influence your likely responsiveness to each medication, helping PlexusDx match you to the right choice at $99 after your first month of treatment.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Understanding What Are Doses of Ozempic: Your Guide to a Healthier Path
How Soon Do You Feel the Side Effects of Ozempic?